A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

Hypertension

Volumn 25, Issue 6, 1995, Pages 1345-1350

  Gradman, Alan H ^b   Arcuri, Karen E ^b   Goldberg, Allan I ^b   Ikeda, Leila S ^b   Nelson, Edward B ^b   Snavely, Duane B ^b   Sweet, Charles S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

angiotensin II; angiotensin converting enzyme inhibitors; dose response relationship, drug; enalapril; hypertension, essential; losartan

Indexed keywords

ENALAPRIL MALEATE; LOSARTAN POTASSIUM; PLACEBO;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 0029065095     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.25.6.1345     Document Type: Article

References (21)

1. Catt KJ, Mendelsoln FAC, Millan A, Aguilera G. The role of angiotensin II receptors in vascular regulation. J Cardiovasc Pharmacol. 1984;6:S575-S586.
2. Gunther S, Gimbrone MA Jr, Alexander RW. Identification and characterization of high affinity vascular angiotensin II receptor in rat mesenteric artery. Circ Res. 1980;47:278-286.
3. Hall JE, Guyton AC. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin angiotensin system. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press Publishers; 1990:1105-1129.
4. Garrison JC, Peach MJ. Renin and angiotensin. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press; 1990:749-763.
5. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;32:135-165.
6. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens. 1992;5(part 2):221S-235S.
7. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM. In vivo pharmacology of DuP 753. Am J Hypertens. 1991;4:288S-298S.
8. Siegl PKS. Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J Hypertens. 1993;11:S19-S22.
9. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM. Nonpeptide angiotensin II antagonists, XI: pharmacology of Exp3174, an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;255:211-217.
10. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PBMWM, Brunner HR. Oral administration of DuP 753, a specific angiotensin II receptor antagonist to normal male volunteers, inhibits pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
11. Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PBMWM, Brunner HR. Dose-response relationships following oral administration of DuP753 to normal humans. Am J Hypertens. 1991;4(part 2):350S-353S.
12. Munafo A, Christen Y, Nussberger J, Shum L, Borland M, Lee RJ, Waeber B, Biollaz J, Brunner HR. Drug concentration response relationship in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 1992;51:513-521.
13. Nelson EB, Merrill DM, Sweet CS, Bradstreet T, Panebianco D, Byyny R, Herman T, Lasseter K, Levy B, Lewis G, McMahon FG, Reeves R, Ruff S, Shepherd A, Weidler D, Irvin JD. Efficacy and safety of oral MK-954 (DuP 753), an angiotensin receptor antagonist, in essential hypertension. J Hypertens. 1991;9(suppl 6):S468-S469. Abstract.
14. Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist in patients with essential hypertension. Am J Hypertens. 1994;7:1035-1040.
15. SAS Institute Inc. SAS/STAT User's Guide, Release 6.03 Edition. Cary, NC: SAS Institute Inc; 1988:1028.
16. Hudson D. Fitting segmented curves whose join points have to be estimated. J Am Stat Assoc. 1966;61:1097-1129.
17. Brunner DB, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H, Brunner HR, Schelling JL. Effect of a new angiotensin converting enzyme inhibitor MK421 and its lysine analog on the components of the renin system in healthy subjects. Br J Clin Pharmacol. 1981; 11:461-467.
18. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor, MK-421. Lancet. 1981;2:543-547.
19. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: biochemistry and molecular biology. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press Publishers; 1990:1217-1231.
20. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol. 1993;22:579-584.
21. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993;6:28-32.